临床阶段生物技术公司增益治疗公司宣布了一项公开募股普通股和认股权证的计划。公司旨在利用净收益加速其主导产品候选物GT-02287的开发，该产品聚焦于神经退行性疾病领域，包括GBA1帕金森病。Newbridge证券公司被指定为独家簿记管理人。募股将以招股说明书形式推进，最终条款将基于定价时的市场条件确定。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.